IMU.ASX: FDA Supports Strategy Toward Registration for Azer-cel

FDA Supports Strategy Toward Registration for Azer-cel

Stock	Imugene Ltd (IMU.ASX)
Release Time	8 Dec 2025, 8:49 a.m.
Price Sensitive	Yes

This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA. The summaries are generated by large language models so please interpret with care.

FDA Supports Strategy Toward Registration for Azer-cel

Key Points

FDA confirmed data from current Phase 1b study supports moving to a Phase 3 Registrational study
3rd line and later DLBCL including patients who relapsed after autologous CAR-T accepted as the registrational study population
FDA endorsed Imugene's dual end point strategy with ORR and durability for accelerated approval and PFS for full approval

Full Summary

Imugene Limited has received written minutes from the US Food and Drug Administration (FDA) following a recent Type C meeting regarding the registrational pathway for azercabtagene zapreleucel (azer-cel), its allogeneic CAR T therapy. The FDA confirmed that the data from the current Phase 1b study with the azer-cel +IL-2 dosing regimen (including lymphodepletion conditioning) and the safety profile support moving towards a Phase 3 Registrational study. The FDA accepted 3rd line and later diffuse large B-cell lymphoma (DLBCL) patients, including those who have relapsed after autologous CAR-T, as the registrational study population - a major high-need setting. The FDA endorsed Imugene's dual endpoint strategy, with Overall Response Rate (ORR) and durability for accelerated approval and Progression Free Survival (PFS) for full approval, and confirmed that one randomized study can support both endpoints with adequate follow-up. The FDA also agreed that Imugene's Chemistry Manufacturing Controls (CMC) program is suitable for initiating a registrational study. The clinical activity for azer-cel continues to strengthen, with an 82% ORR in CAR-T relapsed DLBCL and an 83% ORR in CAR-T naïve indications across multiple CD19-positive cancers.

Guidance

The FDA confirmed support of a single, randomized study using Overall Response Rate (ORR) with durability for accelerated approval and Progression Free Survival (PFS) for full approval.

Outlook

Imugene will compile the positive feedback received from the FDA to inform the potential pivotal study protocol, operational plans, and additional clinical program data. This will be done in alignment with the FDA's supportive minutes as the company prepares for future meetings to seek further guidance on the pivotal programs and statistical analysis plan.